Ginsenoside Re Reduces A Beta Production By Activating Ppar Gamma To Inhibit Bace1 In N2a/App695 Cells

Guoqiong Cao,Ping Su,Shuai Zhang,Limin Guo,Haijing Zhang,Yuexia Liang,Chunxia Qin,Wensheng Zhang
DOI: https://doi.org/10.1016/j.ejphar.2016.11.006
IF: 5.195
2016-01-01
European Journal of Pharmacology
Abstract:Alzheimer's disease (AD) is a neurodegenerative disease characterized by beta-amyloid protein (A beta) deposition. Reducing the A beta load may be a new perspective for AD treatment. Ginsenoside Re is an extract from Panax notoginseng, which is a well-known traditional Chinese medicine that has been used for the treatment of various diseases for years. Ginsenoside Re has been reported to decrease A beta in Alzheimer's disease animal models, but the mechanism has not been fully elucidated. In the present study, we investigated the mechanism of ginsenoside Re. Our results showed that ginsenoside Re decreased the AP levels in N2a/APP695 cells. AP peptides are generated by beta-secretase (beta-site amyloid precursor protein cleaving enzyme 1 (BACE1)) and ysecretase. We found that ginsenoside Re decreased the BACE1 mRNA and protein levels and inhibited BACE1 activity in the N2a/APP695 cells. Peroxisome proliferator-activated receptor-gamma (PPAR gamma) is a transcription factor that regulates the activity of the BACE1 promoter, and activating PPAR gamma can inhibit BACE1. The results also showed that ginsenoside Re significantly increased the PPAR gamma protein and mRNA levels. These effects of ginsenoside Re on BACE1 could be effectively inhibited by the PPAR gamma antagonist GW9662. These findings indicate that ginsenoside Re inhibits BACE1 through activation of PPAR gamma, which ultimately reduces the generation of A beta(1-40) and A beta(1-42). Therefore, ginsenoside Re may be a promising agent for the modulation of Al related pathology in AD.
What problem does this paper attempt to address?